William Blair Has Positive Outlook of DVAX FY2024 Earnings

Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) - Investment analysts at William Blair lifted their FY2024 earnings estimates for shares of Dynavax Technologies in a research note issued on Thursday, November 7th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will earn $0.15 per share for the year, up from their previous estimate of $0.12. The consensus estimate for Dynavax Technologies' current full-year earnings is $0.18 per share. William Blair also issued estimates for Dynavax Technologies' Q2 2025 earnings at $0.10 EPS, Q3 2025 earnings at $0.11 EPS and FY2025 earnings at $0.27 EPS.

A number of other equities research analysts have also recently weighed in on DVAX. HC Wainwright restated a "buy" rating and set a $29.00 price objective on shares of Dynavax Technologies in a research note on Friday. The Goldman Sachs Group cut their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a "neutral" rating on the stock in a report on Thursday, August 8th.

Dynavax Technologies Stock Up 5.0 %

NASDAQ:DVAX traded up $0.65 during trading hours on Monday, reaching $13.66. The company's stock had a trading volume of 7,176,190 shares, compared to its average volume of 2,138,794. The stock has a 50 day moving average price of $11.16 and a two-hundred day moving average price of $11.24. The company has a debt-to-equity ratio of 0.35, a quick ratio of 13.18 and a current ratio of 14.18. The company has a market capitalization of $1.79 billion, a P/E ratio of 105.01 and a beta of 1.34. Dynavax Technologies has a 12 month low of $9.74 and a 12 month high of $15.01.

Institutional Investors Weigh In On Dynavax Technologies

A number of large investors have recently bought and sold shares of DVAX. Mizuho Markets Americas LLC lifted its stake in Dynavax Technologies by 16.9% during the 1st quarter. Mizuho Markets Americas LLC now owns 852,057 shares of the biopharmaceutical company's stock valued at $10,574,000 after acquiring an additional 123,300 shares during the period. Assenagon Asset Management S.A. acquired a new position in Dynavax Technologies during the third quarter valued at $8,291,000. Millennium Management LLC purchased a new stake in Dynavax Technologies in the second quarter valued at $17,615,000. Vanguard Group Inc. boosted its holdings in Dynavax Technologies by 1.4% in the first quarter. Vanguard Group Inc. now owns 9,402,246 shares of the biopharmaceutical company's stock valued at $116,682,000 after purchasing an additional 126,458 shares during the last quarter. Finally, Bank of Montreal Can grew its position in Dynavax Technologies by 15.2% during the 2nd quarter. Bank of Montreal Can now owns 994,632 shares of the biopharmaceutical company's stock worth $11,309,000 after purchasing an additional 130,893 shares during the period. Hedge funds and other institutional investors own 96.96% of the company's stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.